卫信康(603676) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 was CNY 1,300,234,520.39, representing a decrease of 1.69% compared to CNY 1,322,649,286.86 in 2023[22]. - The net profit attributable to shareholders of the listed company reached CNY 246.17 million, a year-on-year increase of 15.02%[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 201.39 million, up 22.86% year-on-year[23]. - Operating cash flow amounted to CNY 372.78 million, representing a 54.61% increase compared to the previous year[23]. - Basic earnings per share increased to CNY 0.57, a 14.00% rise from the previous year[24]. - Total revenue for the year was CNY 1.30 billion, a decrease of 1.69% compared to the previous year[34]. - The total cash dividend distributed for the year, including interim dividends, amounted to CNY 148,316,426.97, which is 60.25% of the net profit attributable to shareholders[6]. - The total amount spent on share repurchases during the year was CNY 29,983,682.50, bringing the combined total of cash dividends and repurchase amounts to CNY 178,300,109.47, or 72.43% of the net profit attributable to shareholders[6]. Dividend Policy - The proposed cash dividend for 2024 is CNY 1.80 per 10 shares, totaling CNY 77,820,264.00 based on the adjusted total share capital of 432,334,800 shares[6]. - The total cash dividend distributed in the last accounting year was 178.3 million CNY, which represents 72.43% of the net profit attributable to ordinary shareholders[185]. - The cumulative cash dividend amount over the last three accounting years was 374.6 million CNY (including tax)[186]. Risk Management - The company has not identified any significant risks that could materially impact its operations during the reporting period[9]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company emphasizes the importance of product quality and adheres to the latest GMP and GSP standards to mitigate quality risks, ensuring product safety and reducing potential impacts on operational performance[148]. - The company is actively managing R&D risks associated with high investment and long cycles, implementing effective risk assessment and control mechanisms to ensure product development remains manageable[149]. Research and Development - The company has over 40 new product projects in development, with 5 expected to receive approval by 2025[42]. - The company emphasizes R&D innovation based on clinical needs, aiming to develop new products with independent intellectual property rights[56]. - The company is focused on expanding its product offerings in the parenteral nutrition market, targeting both adult and pediatric populations[60]. - The company aims to enhance its R&D capabilities and focus on innovative drug development, particularly in perioperative and pediatric medication[137]. Product Development and Market Access - The company has completed access to 31 provincial-level administrative regions for its injectable multivitamins product[34]. - The pediatric multivitamin injection achieved sales revenue of CNY 69.70 million in 2024, representing a year-on-year growth of 53.16%[36]. - The company has completed market access for the pediatric compound amino acid injection in 30 provincial administrative regions by the end of the reporting period[36]. - The company has obtained drug registration certificates for four products, including aspartate potassium injection and multiple trace element injection (I)[41]. - The company has completed market access for the inhaled acetylcysteine solution in 27 provincial administrative regions by the end of the reporting period[37]. Corporate Governance - The company has established a governance structure that includes a board of directors with 7 members, including 3 independent directors with expertise in accounting, law, and pharmaceuticals, ensuring compliance with legal requirements[152]. - The company has a performance evaluation and incentive mechanism in place, assessing senior management and employees annually based on company performance and individual contributions, fostering a fair and efficient work environment[153]. - The company has conducted its annual shareholder meeting, approving all 15 proposals, including the annual financial report and profit distribution plan, ensuring transparency and shareholder engagement[155]. Environmental Responsibility - The company invested 2.2885 million yuan in environmental protection during the reporting period[194]. - The company’s wastewater treatment capacity is 200 m³ per day, with a treatment process that meets the B-level standards of the urban sewage discharge quality[197]. - The company has achieved a 100% compliance rate for solid waste disposal, with no incidents of environmental pollution or occupational accidents reported[198]. - The company ensures compliance with labor laws and occupational health regulations to create a healthy and safe working environment for employees[200].